secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2023-12-01T23:59:59+00:00
Accession:  0001493152-23-043393
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 1.02, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

AgeX Therapeutics COO to depart as Juvenescence terminates services agreement; $3.9M debt
--------------------------------------------------------------------------------

- Juvenescence notified AgeX it is terminating the agreement that provided Nafees Malik as COO; termination effective Dec 31, 2023.
- Dr. Malik's engagement as COO of AgeX and its subsidiary Reverse Bioengineering ends December 27, 2023.
- As of Nov 27, 2023, AgeX owed Juvenescence $3.9 million in secured loans and fees.
- Juvenescence, AgeX's largest shareholder (79.4% of outstanding common shares), provided Dr. Malik's services at 85% cost.
- No replacement for COO has been announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315223043393/0001493152-23-043393-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315223043393/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-043393

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer